S 18523

Drug Profile

S 18523

Latest Information Update: 03 Nov 2003

Price : $50

At a glance

  • Originator Servier
  • Class Analgesics; Anti-inflammatories; Dipeptides
  • Mechanism of Action Neurokinin 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Inflammation; Pain; Respiratory tract disorders

Most Recent Events

  • 03 Nov 2003 No development reported - Preclinical for Respiratory tract disorders in France (unspecified route)
  • 03 Nov 2003 No development reported - Preclinical for Inflammation in France (unspecified route)
  • 02 Sep 1998 No-Development-Reported for Pain in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top